治療に耐性のある重度のうつ病を患っている高齢者
1Department of Psychiatry and Behavioral Sciences, UW AIMS Center, USA.
JAMA
|September 6, 2012
まとめ
高齢者のうつ病の効果的な管理には,スクリーニング,治療開始,モニタリングが含まれます. 共同介護モデルは,晩年のうつ病の治療結果を大幅に改善します.
科学分野:
- ゲリアトリクス ゲリアトリクス
- 精神科医は精神病を患っている.
- 公衆衛生は公衆衛生である.
背景:
- 晩年のうつ病は,高齢者の間で蔓延し,衰弱し,高価な状態です.
- 早期発見と効果的な介入は,この集団におけるうつ病の管理に不可欠です.
研究 の 目的:
- 高齢患者のうつ病の検出と治療のための効果的な戦略を要約する.
- 晩年のうつ病の管理に体系的なアプローチの重要性を強調する.
主な方法:
- 晩年のうつ病の検出と治療のための効果的な戦略のレビュー.
- 長期にわたるうつ病を患っている69歳の女性のケースイラスト.
- 標準評価スケールを用いたスクリーニングと,エビデンスに基づく治療を開始することを重視する.
主要な成果:
- スクリーニング,治療開始 (薬剤または心理療法),症状モニタリングが鍵です.
- 反応しない症例では,精神科の診察,治療調整,または電気療法が必要になる可能性があります.
- メンテナンス治療と再発防止の計画は,長期的な回復に不可欠です.
結論:
- 寛解には,一貫したモニタリングと適応的な治療を含む多面的なアプローチが必要である.
- プライマリケアとメンタルヘルス専門医を統合した共同ケアプログラムは,非常に効果的です.
- ライフスタイルの変更を含む再発予防戦略は,再発のリスクを軽減します.
さらに関連する動画
関連する概念動画
Long-term Depression
27.3K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
27.3K
Long-term Depression
2.6K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.6K
Psychosis: Goals of Pharmacotherapy
713
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
713
Antidepressant Drugs: MAOIs and Other Agents
1.3K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.3K
Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Electroconvulsive Therapy
2.6K
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
2.6K


